Anesthesia for suboccipital craniotomy in a patient with lymphangioleiomyomatosis: a case report.
Case Rep Pulmonol., 2012:804789 (2012)
Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.
Mol. Ther., Jan;20(1):37-45 (2012)
Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.
Neuro-oncology., Feb;14(2):132-44 (2012)
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
J. Natl. Cancer Inst., Jan;104(1):42-55 (2012)
Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.
Mol. Ther., Jun;16(6):1041-7 (2008)
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.
Proc. Natl. Acad. Sci. U.S.A., Mar;106(12):4822-7 (2009)
Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells.
Clin. Cancer Res., Dec;14(23):7711-6 (2008)
Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.
Cancer Gene Ther., Jul;16(7):551-60 (2009)
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.
Cancer Res., Apr;69(8):3472-81 (2009)
Genetic determinants of hearing loss associated with vestibular schwannomas.
Otol. Neurotol., Aug;30(5):661-7 (2009)
Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.
Gene Ther., Dec;16(12):1477-82 (2009)
Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.
Gene Ther., Jun;17(6):805-10 (2010)
Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication.
Cancer Res., May;70(10):3890-5 (2010)
A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.
Clin. Cancer Res., Jun;17(11):3686-96 (2011)
Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.
BMC Biotechnol., 6:40 (2006)
Oncolytic viral therapies - the clinical experience.
Oncogene., Nov;24(52):7802-16 (2005)
Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Mol. Ther., Dec;14(6):789-97 (2006)
Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
Cancer Res., Oct;66(20):10127-35 (2006)
Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Clin. Cancer Res., Nov;12(22):6791-9 (2006)
Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Cancer Res., Jan;67(2):440-4 (2007)
Oncolytic herpes simplex virus therapy for peripheral nerve tumors.
Neurosurg Focus., 22(6):E4 (2007)
Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.
Clin. Cancer Res., Oct;13(19):5897-902 (2007)
Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.
Cancer Res., Oct;67(19):9371-9 (2007)
Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
Proc. Natl. Acad. Sci. U.S.A., May;98(11):6396-401 (2001)
Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates.
Hum. Gene Ther., May;12(8):999-1010 (2001)
Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain.
Gene Ther., Apr;12(8):647-54 (2005)
Psychosurgery: past, present, and future.
Brain Res. Brain Res. Rev., Jun;48(3):409-19 (2005)
Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Cancer Gene Ther., Mar;13(3):253-65 (2006)
Loss of chromosome 22 alleles in human sporadic spinal schwannomas.
Ann. Neurol., Feb;29(2):183-6 (1991)
Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene.
New Biol., Jun;3(6):608-14 (1991)
Cingulotomy for refractory obsessive-compulsive disorder. A long-term follow-up of 33 patients.
Arch. Gen. Psychiatry., Jun;48(6):548-55 (1991)
Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
J. Natl. Cancer Inst., Jan;98(1):38-50 (2006)
The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
J. Neurooncol., May;88(1):43-50 (2008)
Differential modulation of malignant peripheral nerve sheath tumor growth by omega-3 and omega-6 fatty acids.
Oncogene., Mar;24(14):2367-74 (2005)
Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.
Mol. Ther., Oct;2(4):324-9 (2000)
Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.
Mol. Ther., Dec;2(6):588-95 (2000)
In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Cancer Res., Jan;61(1):153-61 (2001)
The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells.
Oncogene., Jan;20(1):97-105 (2001)
Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation.
Cancer Res., Apr;61(7):3009-15 (2001)
Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model.
Exp. Neurol., May;169(1):64-71 (2001)
Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine.
Gene Ther., Feb;8(4):332-9 (2001)
Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
Cancer Gene Ther., Jun;7(6):939-46 (2000)
Craniofacial hemangiopericytoma associated with oncogenic osteomalacia: case report.
J. Neurooncol., 46(3):241-7 (2000)
Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.
Neoplasia., Jun;1(2):162-9 (1999)
A vascular sarcoid mass mimicking a convexity meningioma.
Neuroradiology., Mar;42(3):195-8 (2000)
Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice.
J. Virol., Apr;74(8):3832-41 (2000)
Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy.
Hum. Gene Ther., Nov;10(17):2869-78 (1999)
In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.
J. Immunol., May;160(9):4457-64 (1998)
Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.
Hum. Gene Ther., Oct;9(15):2177-85 (1998)
Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity.
Hum. Gene Ther., Feb;10(3):385-93 (1999)
Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates.
J. Virol., Aug;73(8):6319-26 (1999)
Aberrant cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type-1.
J. Invest. Dermatol., Sep;113(3):398-402 (1999)
Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo.
Gene Ther., Apr;6(4):564-72 (1999)
Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus.
Hum. Gene Ther., Nov;10(17):2741-55 (1999)
Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma.
Cancer Gene Ther., 4(4):222-8 (1997)
Transcriptional targeting of herpes simplex virus for cell-specific replication.
J. Virol., Jul;71(7):5124-32 (1997)
Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
Mol. Pharmacol., Aug;50(2):236-42 (1996)
Gene therapies for glioblastomas.
Baillieres Clin Neurol., Jun;5(2):413-24 (1996)
Expression of L1 in primary astrocytes via a defective herpes simplex virus vector promotes neurite outgrowth and neural cell migration.
Brain Res. Mol. Brain Res., Dec;43(1-2):311-20 (1996)
Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1.
Cancer Res., Nov;55(21):4752-6 (1995)
[Gene therapy for brain tumors: experimental treatment of malignant brain tumors using recombinant herpes simplex virus type 1 (series 7)].
No Shinkei Geka., Apr;23(4):285-92 (1995)
Antisense expression of protein kinase C alpha inhibits the growth and tumorigenicity of human glioblastoma cells.
Neurosurgery., Nov;35(5):904-8; discussion 908-9 (1994)
AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo.
Neurosurgery., May;34(5):869-75; discussion 875 (1994)
Enhanced in vitro uptake and retention of 3H-tetraphenylphosphonium by nervous system tumor cells.
J. Neurosurg., Jan;74(1):116-22 (1991)
CNS tumor therapy by attenuated herpes simplex viruses.
Gene Ther., 1 Suppl 1:S78 (1994)
Clinical mutations in the L1 neural cell adhesion molecule affect cell-surface expression.
J. Neurosci., Aug;20(15):5696-702 (2000)
Benign spinal nerve sheath tumors: their occurrence sporadically and in neurofibromatosis types 1 and 2.
J. Neurosurg., Feb;74(2):248-53 (1991)
Molecular neurosurgery for glial and neuronal disorders.
Stereotact Funct Neurosurg., 59(1-4):92-9 (1992)
Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study.
Exp. Neurol., Mar;115(3):303-16 (1992)
Laser-induced fluorescence: experimental intraoperative delineation of tumor resection margins.
J. Neurosurg., Apr;76(4):679-86 (1992)
Growth of human acoustic neuromas, neurofibromas and schwannomas in the subrenal capsule and sciatic nerve of the nude mouse.
J. Neurooncol., Oct;14(2):101-12 (1992)
Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells.
J. Neurosci. Res., Nov;33(3):493-503 (1992)
Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir.
Neurosurgery., Apr;32(4):597-603 (1993)
An experimental model of retrovirus gene therapy for malignant brain tumors.
J. Neurosurg., Jul;79(1):104-10 (1993)
Cingulotomy in a case of concomitant obsessive-compulsive disorder and Tourette's syndrome.
Arch. Gen. Psychiatry., Jan;51(1):73-4 (1994)
Seizures due to metrizamide myelography in patients with acute cervical spine injury.
Neurosurgery., Feb;10(2):266-7 (1982)
Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone.
J. Neurosurg., Sep;73(3):429-35 (1990)
A new 1.9-mu wavelength laser for neurosurgery.
J. Neurosurg., Oct;73(4):611-4 (1990)
Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line.
J. Neurosci. Res., Nov;27(3):427-39 (1990)
Co-Author, "Identification of diagnostic serum protein profiles of glioblastoma patients"
Journal of Neuro-oncology
Co-Author, "Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication"
Co-Author, "Genetic determinants of hearing loss associated with vestibular schwannomas"
Otology & Neurotology
Co-Author, "Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors"
Co-Author, "Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy"
Proceedings of the National Academy of Science
Co-Author, "Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells"
Cancer Gene Therapy
Co-Author, "Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation"
Co-Author, "Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells"
Clinical Cancer Research
Co-Author, "Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes"
American Journal of Pathology
Co-Author, "The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma"
Journal of Neuro-oncology